German pharmaceutical company Bayer AG has been asked to stop the phase III trials of the drug Alpharadin. Patients who were receiving placebo will be offered the new medicine. The safety and tolerability of Alpharadin were consistent during Phase I and Phase II trial outcomes.
Alpharadin, or radium-223 chloride is exclusively licensed from Norwegian partner Algeta ASA. The drug met its primary endpoint by improving overall survival significantly in patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases.
AdvertisementThe median overall survival rate was 14 months for patients treated with Alpharadin, compared with 11.2 months.